Menu Back toPopulation Diversity Considerations in Clinical Trials

DIA 2021 Global Annual Meeting

Population Diversity Considerations in Clinical Trials

Session Chair(s)

Freda  Cooner, PhD

Freda Cooner, PhD

  • Director, Global Biostatistics
  • Direction, Amgen, United States
To promote health equity and reduce disparities in racial and ethnic minorities, this session will discuss potential trial designs and statistical methods to increase the participation of minorities and/or diversity of populations in clinical trials.
Learning Objective : Discuss considerations and strategies in clinical trials' planning and conduct to enhance population diversity; Describe statistical challenges in clinical trial subgroup disparities; Identify potential trial designs and methodologies to mitigate disparity factors in the patient population.


Demissie  Alemayehu, PhD

Considerations on the Use of Analytics and Technology to Enhance Diversity in Clinical Trials

Demissie Alemayehu, PhD

  • Vice President, Biostatistics
  • Pfizer Inc, United States
Laura  Fernandes, PhD

Disparities by Demographic Subgroups in Clinical Trials Submitted to the FDA

Laura Fernandes, PhD

  • United States
Ruthie  Davi, PhD, MS


Ruthie Davi, PhD, MS

  • Vice President, Data Science and Statistician
  • Medidata, a Dassault Systèmes company, United States